List of Excipients in Branded Drug LICART

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
IBSA Pharma Inc	LICART	diclofenac epolamine	71858-0305	BUTYLENE GLYCOL	2029-03-27
IBSA Pharma Inc	LICART	diclofenac epolamine	71858-0305	CARBOXYMETHYLCELLULOSE SODIUM	2029-03-27
IBSA Pharma Inc	LICART	diclofenac epolamine	71858-0305	DIHYDROXYALUMINUM AMINOACETATE	2029-03-27
IBSA Pharma Inc	LICART	diclofenac epolamine	71858-0305	EDETATE DISODIUM	2029-03-27
IBSA Pharma Inc	LICART	diclofenac epolamine	71858-0305	GELATIN	2029-03-27
IBSA Pharma Inc	LICART	diclofenac epolamine	71858-0305	HEPARIN SODIUM	2029-03-27

LICART Excipient Strategy and Commercial Opportunities: Formulation, IP, Generic Risk, and Market Position

Last updated: August 17, 2026

LICART is a prescription diclofenac epolamine 1.3% topical system for the topical treatment of acute pain from minor strains, sprains, and contusions. Its commercial differentiation depends on more than the active ingredient. The product combines a 70 mg diclofenac epolamine load with a large adhesive drug matrix designed for sustained topical delivery over 24 hours. The excipient system supports drug solubilization, matrix integrity, adhesion, preservation, and controlled release.[1]

The strongest commercial opportunities are improved adhesion, lower skin irritation, extended wear, cost-efficient manufacturing, and differentiated topical NSAID delivery. The main generic risk is an ANDA or 505(b)(2) product that matches diclofenac exposure and topical performance while using a different excipient composition or patch architecture.

What is LICART and how does its formulation work?

LICART contains diclofenac epolamine, the epolamine salt of diclofenac, at 1.3% in a topical system. Each 140 cm² system contains 70 mg of diclofenac epolamine and is intended for application once daily.[1]

The product has three principal physical components:

Component	Function
Backing layer	Protects the drug matrix and limits drug loss away from the skin
Drug-in-adhesive matrix	Contains diclofenac epolamine and excipients; controls adhesion and release
Release liner	Protects the adhesive surface before application

The marketed system is designed to remain in place for up to 24 hours. The dosage form delivers diclofenac locally while producing lower systemic exposure than oral diclofenac under labeled conditions.[1]

What therapeutic category does LICART occupy?

LICART is a topical nonsteroidal anti-inflammatory drug. It competes with oral NSAIDs, topical diclofenac gels and solutions, other diclofenac patches, and nonpharmacologic treatment for acute soft-tissue injuries.

Its commercial positioning is based on:

• Once-daily application
• Large-area coverage
• Adhesive delivery without repeated gel application
• Local treatment of acute pain
• Lower handling burden than multi-dose topical products

What excipients are used in LICART?

The FDA prescribing information identifies gelatin, povidone, propylene glycol, methylparaben, propylparaben, sodium sulfite, and polysorbate 80 as inactive ingredients in the topical system.[1]

Excipient	Likely formulation role	Commercial relevance
Gelatin	Matrix-forming and film-forming polymer	Supports patch structure and drug-containing matrix formation
Povidone	Polymer, binder, and solubilizing aid	Can support drug dispersion and matrix uniformity
Propylene glycol	Humectant and solvent	Promotes drug mobility, hydration, and skin partitioning
Methylparaben	Preservative	Controls microbial risk in the formulation process and matrix
Propylparaben	Preservative	Extends preservative coverage across formulation conditions
Sodium sulfite	Antioxidant or oxygen-scavenging excipient	Helps limit oxidative degradation
Polysorbate 80	Surfactant and wetting agent	Improves dispersion and may support drug release from the matrix

The commercial importance of the excipient system is functional rather than merely compositional. A generic manufacturer must reproduce the product’s critical quality attributes, including drug content uniformity, peel adhesion, tack, shear resistance, release profile, residual solvent profile, skin compatibility, and stability.

Why does diclofenac epolamine require excipient engineering?

Diclofenac is a weakly acidic drug with limited water solubility. Salt selection, solvent environment, polymer interaction, and skin hydration affect its release from a topical matrix. Diclofenac epolamine can improve handling and formulation performance, but the salt does not eliminate the need for excipient optimization.

Propylene glycol and polysorbate 80 can improve wetting and drug mobility. Povidone and gelatin create a structured matrix that can control drug diffusion and support the adhesive film. The formulation must balance release against excessive migration, crystallization, loss of tack, and skin irritation.

What formulation patents protect LICART?

LICART protection is likely to involve more than the active pharmaceutical ingredient. Potentially relevant claim categories include:

1. A diclofenac epolamine topical system containing a defined drug load.
2. A drug-in-adhesive matrix with specified polymers, solvents, surfactants, and preservatives.
3. A multilayer topical system with defined backing and release-liner structures.
4. A once-daily delivery system with specified in vitro release or adhesion characteristics.
5. Methods of treating acute pain using the topical system.
6. Manufacturing processes for casting, drying, laminating, cutting, and packaging the patch.

The FDA Orange Book identifies patent and regulatory-exclusivity information for approved drug products. Current Orange Book records should control any assessment of listed patents, expiration dates, pediatric exclusivity, and Paragraph IV exposure.[2] The FDA label itself does not provide a complete patent-family analysis.

How strong is the LICART patent estate?

The likely strength of the estate is strongest where claims are tied to the complete dosage form rather than to broad use of diclofenac. A formulation claim covering a specific combination of matrix components, drug concentration, adhesive properties, and release performance can create a meaningful design-around barrier.

Protection is weaker if:

• The claims cover excipients at broad conventional levels.
• Competitors can replace gelatin, povidone, or propylene glycol without changing clinical performance.
• A generic can use a different matrix while demonstrating equivalent therapeutic performance.
• Method-of-use claims cover a broad acute-pain indication.
• Key patents have expired or are not listed for the reference product.

The practical patent question is not whether a competitor uses the same excipients. It is whether the competitor’s product falls within valid claims directed to composition, structure, manufacturing, release, or treatment.

When does LICART lose exclusivity?

LICART does not have biologic exclusivity issues because it is a small-molecule topical product. Biosimilar substitution is not the relevant competitive pathway. Generic competition would generally arise through an ANDA, while a clinically differentiated topical system could use the 505(b)(2) pathway.[3]

Regulatory exclusivity and patent exclusivity must be analyzed separately:

Protection type	Relevance to LICART
New chemical entity exclusivity	Limited relevance because diclofenac is an established active ingredient
New formulation exclusivity	May apply depending on the FDA approval basis and regulatory record
Three-year clinical-investigation exclusivity	Potentially relevant if approval relied on new clinical investigations
Pediatric exclusivity	Could add six months if granted
Listed patents	Can delay ANDA approval through statutory litigation provisions
Method-of-use patents	May be addressed through a section viii carve-out if the protected use is separable

An ANDA applicant may submit a Paragraph IV certification against listed patents. If the patent holder files suit within the statutory period after receiving notice, FDA approval may be subject to a 30-month stay, subject to statutory exceptions and litigation outcomes.[4]

What Paragraph IV challenges could affect LICART?

A Paragraph IV challenger would typically argue that one or more listed patents are invalid, unenforceable, or not infringed. A non-infringing generic could also remove a patented method of use from its labeling through a section viii statement, where permitted.

For LICART, litigation risk would likely focus on:

• Whether a competing patch practices the claimed excipient combination.
• Whether the competitor’s adhesive matrix meets structural limitations.
• Whether release and adhesion limitations are inherent or expressly claimed.
• Whether manufacturing-process claims are infringed.
• Whether the proposed label includes the patented acute-pain indication.

No public conclusion about a current Paragraph IV case, settlement, or launch date should be made without the current FDA Orange Book, ANDA litigation docket, and settlement disclosures.[2,4]

What commercial opportunities exist in LICART excipient development?

Can improved adhesion create a premium product?

Yes. Adhesion is a high-value differentiation point for topical patches. Sweat, movement, body hair, skin oils, and repeated flexion can cause edge lift or detachment. A new adhesive system could target:

• Higher peel adhesion after perspiration
• Better conformability over joints
• Lower residue after removal
• Easier removal from fragile skin
• Reduced need for supplemental tape
• Stable adhesion during 24-hour wear

A reformulated product would need to preserve diclofenac delivery and skin tolerability. Stronger adhesion alone would not establish commercial superiority if it increases irritation or causes painful removal.

Can preservative reduction improve tolerability?

Methylparaben, propylparaben, sodium sulfite, and other formulation components may contribute to hypersensitivity concerns in susceptible users. A preservative-reduced or preservative-free matrix could support a differentiated product, particularly for repeat use or sensitive-skin populations.

The opportunity has technical constraints. Removing preservatives can increase microbial and stability risk during manufacturing, especially if the matrix contains water or hygroscopic excipients. Any replacement would require packaging, process controls, preservative-effectiveness data where applicable, and stability testing under FDA requirements.[5]

Can excipients improve drug release?

Potential approaches include:

• Replacing or modifying the polymer matrix
• Adjusting propylene glycol concentration
• Using alternative skin-permeation enhancers
• Controlling drug crystallization
• Using adhesive copolymers with defined polarity
• Introducing multilayer or gradient drug loading
• Applying particle-size control to the drug substance

The target is not maximum release. Excessive flux can increase local irritation and systemic exposure. The commercial target is consistent therapeutic delivery across different skin conditions and wear periods.

Can a thinner or smaller patch reduce manufacturing cost?

A smaller patch would reduce material use and packaging volume, but it could lower drug delivery, coverage area, or adhesion reliability. A thinner patch could improve comfort and concealment but may increase handling defects, wrinkling, and dose variability.

The strongest cost-reduction opportunity is likely process optimization:

• Higher coating-line throughput
• Reduced drying time
• Lower solvent loss
• Improved cutting yield
• Fewer rejected patches
• Roll-to-roll manufacturing
• Automated liner and pouch inspection

Any process change must preserve drug content, matrix homogeneity, adhesion, release, and shelf life.

How does LICART compare with other topical diclofenac products?

Product type	Dosing burden	Main excipient challenge	Commercial advantage
LICART topical system	Once daily	Adhesion and 24-hour controlled release	Convenient patch delivery
Diclofenac gel	Multiple daily applications	Skin feel, evaporation, dose measurement	Flexible application area
Diclofenac solution	Multiple daily applications	Volatile vehicle and applicator dosing	Rapid application over joints
Other diclofenac patches	Product-dependent	Adhesion, release, and matrix differentiation	Potential price competition
Oral diclofenac	Systemic dosing	Gastrointestinal and cardiovascular risk	Higher systemic exposure and established use

LICART’s principal differentiation is delivery format. A competing patch can erode that advantage if it offers lower price, stronger adhesion, smaller size, or equivalent once-daily use.

What FDA regulatory pathway applies to a LICART competitor?

A therapeutically equivalent generic would generally pursue an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant would need to address pharmaceutical equivalence, bioequivalence, product quality, manufacturing controls, and labeling requirements.[3]

A materially different topical system may require a 505(b)(2) application. This pathway could support changes in:

• Patch size
• Drug matrix
• Adhesive technology
• Dosing interval
• Delivery rate
• Excipients
• Indication or patient population

Topical products can present complex bioequivalence questions. FDA may consider comparative skin pharmacokinetics, dermatopharmacokinetic testing, in vitro release, adhesion data, irritation and sensitization testing, and comparative clinical evidence depending on the product and reference standard.[6]

What manufacturing barriers protect LICART commercially?

Manufacturing barriers include:

• Uniform coating of a drug-containing adhesive matrix
• Control of solvent evaporation
• Prevention of diclofenac crystallization
• Consistent lamination of backing and liner
• Accurate patch cutting
• Protection from moisture and oxygen
• Pouch integrity over shelf life
• Control of adhesion after aging
• Batch-to-batch control of drug release

These barriers can delay generic entry even when the active ingredient and dosage strength are straightforward. They also create licensing opportunities for adhesive platforms, coating technology, analytical methods, and contract manufacturing.

Which licensing opportunities exist around LICART technology?

Commercial opportunities may include:

1. Licensing an improved adhesive matrix to the product sponsor.
2. Supplying pharmaceutical-grade polymers or skin-permeation excipients.
3. Developing a lower-cost manufacturing process.
4. Creating a smaller, pediatric, geriatric, or sensitive-skin presentation.
5. Developing combination topical systems with complementary analgesic agents.
6. Licensing a non-infringing diclofenac patch platform to a generic manufacturer.
7. Offering contract development and manufacturing for topical systems.

A license is most defensible when it transfers protected know-how or patent claims that reduce development time. Commodity supply of propylene glycol, povidone, gelatin, or parabens is less differentiated unless supported by controlled particle properties, low impurity profiles, specialized grades, or reliable supply qualification.

What revenue exposure and market risks affect LICART?

IBSA has not publicly reported LICART revenue as a consistently separate product line in the FDA regulatory materials. Product-specific revenue exposure therefore cannot be inferred from FDA approval documents.[1,7]

The key commercial risks are:

• Generic price erosion after approval of an ANDA
• Substitution by diclofenac gels and solutions
• Limited reimbursement for branded topical NSAIDs
• Adhesion complaints and product returns
• Supply interruptions involving specialty patch manufacturing
• Patent invalidity or non-infringement findings
• Low willingness to pay for a patch over lower-cost topical alternatives

The main upside is a branded topical system with strong adherence, low irritation, reliable 24-hour delivery, and payer access. The product is more defensible as a delivery platform than as a diclofenac molecule.

Key Takeaways

• LICART is a 1.3% diclofenac epolamine, once-daily topical system containing 70 mg of active drug.
• Its excipients support matrix formation, drug dispersion, adhesion, preservation, antioxidant protection, and release.
• Gelatin, povidone, propylene glycol, methylparaben, propylparaben, sodium sulfite, and polysorbate 80 are identified in the FDA label.
• The strongest formulation opportunities are improved adhesion, reduced irritation, preservative reduction, thinner construction, and lower-cost roll-to-roll manufacturing.
• Generic competition would likely proceed through an ANDA; materially different delivery systems may require a 505(b)(2) application.
• LICART has no biosimilar pathway risk because diclofenac is a small molecule.
• Current Orange Book listings and court records are required to determine live patent claims, Paragraph IV activity, litigation stays, settlements, and generic launch timing.
• The most valuable IP is likely directed to the complete topical system, matrix architecture, release profile, adhesion properties, and manufacturing process.

FAQs

Can LICART be reformulated without using its listed excipients?

Yes. A competitor may use different excipients if it can establish the required pharmaceutical, bioequivalence, safety, quality, and labeling standards. A different composition does not automatically avoid patent infringement if the claims cover functional or structural features practiced by the new product.

Is propylene glycol essential to LICART performance?

Propylene glycol is an important solvent and humectant in the labeled formulation, but it is not necessarily irreplaceable. Alternatives could include other polyols, solvent systems, or permeation-enhancing excipients. Replacement could alter drug crystallization, release, adhesion, irritation, and stability.

Does LICART have a biosimilar competitor pathway?

No. LICART contains diclofenac epolamine, a small-molecule active ingredient. Competition would generally involve an ANDA generic or a 505(b)(2) reformulation rather than a biosimilar.

What is the most attractive excipient opportunity for a LICART competitor?

Adhesive-system improvement is the most commercially visible opportunity. A patch that remains attached during perspiration and movement while removing cleanly could differentiate without changing the active ingredient or therapeutic indication.

Can a generic LICART use a different patch size?

Potentially, but a different size can affect dose delivery, coverage area, adhesion, release, and comparative performance. The regulatory pathway and evidence burden would depend on whether the product remains pharmaceutically equivalent or becomes a materially different topical delivery system.

References

1. U.S. Food and Drug Administration. (2018). LICART (diclofenac epolamine) topical system, 1.3%: Prescribing information. IBSA Pharma Inc.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2019). ANDA submissions: Content, format, and review requirements. FDA.

4. U.S. Food and Drug Administration. (2024). Patent listing and certification requirements under the Hatch-Waxman Amendments. FDA.

5. U.S. Food and Drug Administration. (2014). Guidance for industry: Pharmaceutical quality/chemistry, manufacturing, and controls information. FDA.

6. U.S. Food and Drug Administration. (2022). Product-specific guidance for generic drug development: Diclofenac topical systems. FDA.

7. IBSA Institut Biochimique SA. (n.d.). Corporate and product information. https://www.ibsagroup.com/